ZA200709473B - Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases - Google Patents

Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Info

Publication number
ZA200709473B
ZA200709473B ZA200709473A ZA200709473A ZA200709473B ZA 200709473 B ZA200709473 B ZA 200709473B ZA 200709473 A ZA200709473 A ZA 200709473A ZA 200709473 A ZA200709473 A ZA 200709473A ZA 200709473 B ZA200709473 B ZA 200709473B
Authority
ZA
South Africa
Prior art keywords
combination
imatinib
treating
proliferative diseases
preventing proliferative
Prior art date
Application number
ZA200709473A
Other languages
English (en)
Inventor
Alland Leila
Paul W Manley
Mestan Juergen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200709473B publication Critical patent/ZA200709473B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA200709473A 2005-06-03 2007-11-02 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases ZA200709473B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68775805P 2005-06-03 2005-06-03

Publications (1)

Publication Number Publication Date
ZA200709473B true ZA200709473B (en) 2008-12-31

Family

ID=36968749

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709473A ZA200709473B (en) 2005-06-03 2007-11-02 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Country Status (27)

Country Link
US (2) US7767688B2 (ja)
EP (1) EP1893213B1 (ja)
JP (2) JP5281887B2 (ja)
KR (1) KR101276425B1 (ja)
CN (1) CN101180060B (ja)
AT (1) ATE457727T1 (ja)
AU (1) AU2006255559B2 (ja)
BR (1) BRPI0611506A2 (ja)
CA (1) CA2608814C (ja)
CY (1) CY1110027T1 (ja)
DE (1) DE602006012313D1 (ja)
DK (1) DK1893213T3 (ja)
ES (1) ES2339593T3 (ja)
HK (1) HK1115528A1 (ja)
HR (1) HRP20100265T1 (ja)
IL (1) IL187408A0 (ja)
MA (1) MA29565B1 (ja)
MX (1) MX2007015159A (ja)
NO (1) NO20080037L (ja)
NZ (1) NZ563446A (ja)
PL (1) PL1893213T3 (ja)
PT (1) PT1893213E (ja)
RU (1) RU2430727C2 (ja)
SI (1) SI1893213T1 (ja)
TN (1) TNSN07453A1 (ja)
WO (1) WO2006132930A1 (ja)
ZA (1) ZA200709473B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101276425B1 (ko) * 2005-06-03 2013-06-19 노파르티스 아게 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
EP2382976A1 (en) * 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
CN102719530B (zh) * 2012-05-07 2013-11-06 厦门艾德生物医药科技有限公司 一种用于检测PDGFRα基因突变的引物、探针及试剂盒
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
CN111278466A (zh) 2017-07-26 2020-06-12 夫特弗制药私人有限公司 伊马替尼的液体剂型
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
KR101276425B1 (ko) * 2005-06-03 2013-06-19 노파르티스 아게 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물

Also Published As

Publication number Publication date
RU2007147957A (ru) 2009-07-20
SI1893213T1 (sl) 2010-05-31
JP5281887B2 (ja) 2013-09-04
US20080312252A1 (en) 2008-12-18
US20100190800A1 (en) 2010-07-29
BRPI0611506A2 (pt) 2010-09-14
CA2608814A1 (en) 2006-12-14
AU2006255559A1 (en) 2006-12-14
JP2008542390A (ja) 2008-11-27
KR20080021633A (ko) 2008-03-07
JP2013035853A (ja) 2013-02-21
PL1893213T3 (pl) 2010-08-31
CA2608814C (en) 2013-09-03
US8653093B2 (en) 2014-02-18
DE602006012313D1 (de) 2010-04-01
NO20080037L (no) 2008-01-03
RU2430727C2 (ru) 2011-10-10
US7767688B2 (en) 2010-08-03
IL187408A0 (en) 2011-07-31
TNSN07453A1 (en) 2009-03-17
HRP20100265T1 (hr) 2010-06-30
PT1893213E (pt) 2010-04-19
MA29565B1 (fr) 2008-06-02
EP1893213A1 (en) 2008-03-05
NZ563446A (en) 2011-02-25
AU2006255559B2 (en) 2009-12-17
CN101180060A (zh) 2008-05-14
ES2339593T3 (es) 2010-05-21
WO2006132930A1 (en) 2006-12-14
CN101180060B (zh) 2011-12-28
EP1893213B1 (en) 2010-02-17
MX2007015159A (es) 2008-02-15
HK1115528A1 (en) 2008-12-05
CY1110027T1 (el) 2015-01-14
ATE457727T1 (de) 2010-03-15
DK1893213T3 (da) 2010-06-07
KR101276425B1 (ko) 2013-06-19

Similar Documents

Publication Publication Date Title
WO2007075525A3 (en) Combination of an iap-inhibitor and a taxane7
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
TW200738270A (en) Method of treating depression using a TNFα antibody
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
SI1984357T1 (sl) Spojine 2,4-pirimidindiamina za zdravljenje ali preventivo avtoimunih bolezni
TW200731974A (en) Transdermal system for verenicline
GB0516168D0 (en) Pharmaceutical compounds
TW200800967A (en) Benzimidazole thiophene compounds
TW200731991A (en) Lipophilic di(anticancer drug) compounds, compositions and related methods
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
HK1115528A1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2006060542A3 (en) Formulations of substituted benzoxazoles
WO2007022042A3 (en) Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
TW200638932A (en) CCI-779 polymorph and use thereof
WO2007116029A3 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
EP2099458A4 (en) COMPOUNDS AND METHODS FOR IMAGING AND THERAPY OF ENZYME-MEDIATED TUMORS
WO2007022044A3 (en) Combination of organic compounds
WO2007010013A3 (en) Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
WO2007064997A3 (en) Compounds and methods for inhibiting apoptosis
WO2007010012A3 (en) Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor
TW200714284A (en) Novel method
WO2007047950A3 (en) Use of sumoylation inhibitors for the treatment of neurodegenerative disease